Clinical trials are absolutely necessary in order to make sure a drug works as intended. However, such testing does involve risk, as recently illustrated by Celgene’s decision to stop administering Revlimid® (lenalidomide) in its Phase III ORIGIN® trial because of patient deaths. Suppose you fit a clinical trial’s patient requirements: Would you take the risk?
If you were in a position to do so, would you participate in a clinical trial?
Maybe, if no other treatments worked